On the basis of 32P-postlabeling analysis, treatment of rats with 1-nitropyrene (1-NP) resulted in the formation of multiple DNA adducts in the liver, mammary glands, and peripheral lymphocytes. The one adduct resulting from nitroreduction, N-(deoxyguanosin-8-yl)-1-aminopyrene, constitutes only a minor component among the adducts. In the present study, incubation of calf thymus DNA with mutagenic ring-oxidized metabolites of 1-NP in vitro in the presence and absence of xanthine oxidase also resulted in the formation of multiple adducts. On the basis of their chromatographic behavior, it appears that DNA adducts derived from such metabolites may have been formed in vivo; however, this needs to be confirmed.
Introduction
Nitropolynuclear aromatic hydrocarbons (NO2-PAH) are widely distributed in the environment (1) . Mutagenic activities in bacterial and mammalian systems and tumorigenic activity in laboratory animals of several members of the class of NO2-PAH have been clearly documented (2) (3) (4) (5) .
Risk assessment associated with human exposure to N02-PAH has not of such agents in the environment and their possible involvement in the etiology of some human cancers (6) . Thus, our goal was to develop sensitive analytical methods for detection and quantitation of N02-PAH and their metabolites in biologic fluids and assessment of their adducts with proteins and DNA in humans. Establishing the metabolic profiles of 1-nitropyrene (1-NP) in laboratory animals would be essential for developing sensitive methods for their detection and quantitation in humans. In the mammalian system, 1-NP is metabolized by nitroreduction, ring oxidation, and a combination of both pathways ( Figure 1 ). Studies in our laboratory and elsewhere indicate that simple nitroreduction of 1-NP to yield N-(deoxyguanosin-8-yl)-1-aminopyrene (N-dG-AP) cannot account for the observed DNA adducts in vivo and in vitro (7) (8) (9) (10) (11) (12) . To more clearly define the metabolic activation of 1-NP, structural elucidation of DNA adducts is required. Therefore, some of our previous efforts were directed towards the identification of additional DNA adduct markers derived from ring-oxidized metabolites of 1-NP (13) . Seeking a highly sensitive method, we used the 32P-postlabeling technique (14) to establish fingerprints of the DNA adducts derived from ring-oxidized metabolites of 1-NP in vitro. The resulting 32P-postlabeled adducts were compared with those obtained from rat tissues such as liver, mammary tissues, and peripheral lymphocytes following the administration of 1-NP (12) . In this study, we also present results on hemoglobin binding of 1-NP.
Materials and Methods

Chemicals
Commercial 1-NP (Aldrich Chemical Co., Milwaukee, WI) was purified by column chromatography on silica gel with elution by 10% benzene in hexane. Its purity, assessed by GC with electron capture detection (15) and GC-MS analysis, was >99.9%; no dinitropyrenes were detected. 1-Nitrosopyrene (1-NOP) was synthesized by oxidation of 1-aminopyrene (1-AP) using m-chloroperoxybenzoic acid (mCPBA) as described (16) . 1-Nitro-xhydroxypyrene (1-NP-x-OH, x = 3, 6, or 8) was obtained by nitration of 1-acetoxypyrene followed by deacetylation (16 CH2Cl2 yielded 4,5-epoxy-4,5-dihydro-1-nitropyrene (1-NP-4,5-oxide) and 9,10-epoxy-9, 1 0-dihydro-1 -nitropyrene (1-NP-9,10-oxide) (17) . cis-and trans-4,5-Dihydro-4,5-dihydroxy-1-nitropyrene (cisand trans-1-NP-4,5-DHD) were also synthesized (18 pCi, except for the lowest dose, in which case 2.2 pCi was administered. Twentyfour hours after gavaging, the rats were anesthetized with ether or halothane, and blood was obtained by cardiac puncture (average 8 ml/rat representing approximately 50% of the total blood volume) (22) . The blood was drawn into syringes containing 0.1 ml EDTA solution, 0.25 M, pH 7.4, to prevent clotting. It was then transferred into polypropylene centrifuge tubes (35 ml) and placed on ice. All subsequent steps were carried out at 4°C. The blood was centrifuged at 900g to pack the red blood cells (RBC). The supernatant plasma was drawn off with a Pasteur pipette and processed as described below. The RBC were washed twice with 15-ml portions of 0.9% saline and centrifuged at 900g each time. The supernatant was kept frozen. Cell rupture and release of hemoglobin was minimal as evidenced by the slight coloration of the supernatant. The RBC were then lysed by vortexing with 15 ml ice-cold distilled H20 for 5 min. Ten milliliters of 0.67 M KH2PO4 buffer, pH 6.5, were added, and the solution was centrifuged at 27,000g for 20 min. The supernatant containing the hemoglobin was placed into dialysis tubes (Spectra/Por 4, 14x 103 molecular weight cutoff, Spectrum Medical Industries, Los Angeles, CA) and was dialyzed against distilled H20, 2.5 liters x 4 changes over 4 days. The hemoglobin solutions were frozen at -20°C until analysis. The hemoglobin obtained from each rat was analyzed individually. Five-milliliter aliquots of each test solution were placed in scintillation vials containing 0.5 ml 10 N NaOH; these vials were brought up to 50°C for 2 hr to hydrolyze the hemoglobin. After cooling, 5 ml of 50% H202 was added to bleach the solution. The hemoglobin was isolated as described above, and the bound radioactivity was measured.
Adduct Accumulation during Chronic Dosing. Five male F344 rats (187 ± 5 g bw) were gavaged every Monday, Wednesday, and Friday for 5 weeks with NP (0.1 mCi, 0.006 mole; total dose: 1.8 mCi, 0.011 mole) in trioctanoin. Blood was drawn weekly (0.5 ml/rat) via the orbital sinus on Tuesdays and Thursdays; the hemoglobin was isolated, and the bound radioactivity was quantified.
Isolation and chromatographic analysis of the hemoglobin adducts. The thawed hemoglobin samples were added dropwise to 200 ml of rapidly stirred 1% HC1 in acetone on ice. The globin precipitate was filtered, dried, and kept frozen at -200C for further analysis. The acidic acetone solution was evaporated to dryness under reduced pressure. The residue was resuspended in tetrahydrofuran, the radioactivity was measured, and an aliquot was analyzed by reverse-phase HPLC. The heme fraction that contained radioactivity was treated with H2SO4/ CH3OH to derivatize the carboxylic acid groups on the heme moiety to methyl esters, followed by treatment with zinc acetate to form methylated zinc metalloporphyrins (23) (24) (25) (26) ; it was then analyzed by HPLC. As an alternative approach, the whole hemoglobin was treated in a similar manner; this simultaneously precipitates the protein and derivatizes the heme moiety to the corresponding methyl ester.
Incubations of 1-nitrosopyrene and 1-nitropyrene-4,5-oxide with rat hemoglobin in vitro. Both 1-NOP and 1-NP-4,5-oxide are 1-NP metabolites that are known to bind to DNA. They also represent both metabolism pathways of 1-NP, nitroreduction and ring oxidation. Freshly isolated rat hemoglobin was incubated at room temperature with both compounds for 4.5 hr (27) .
[3H]1-NOP (0.7 pCi, 0.08 pmole) was incubated under both aerobic and anaerobic conditions. The anaerobic conditions were employed to minimize further oxidation of 1-NOP to 1-NP.
[3H]1-NP-4,5-oxide (0.94 pCi, 0.0 13 pM) was incubated under aerobic conditions only.
Statistical Analysis
Each point in Figures 2 and 3A represents the mean ± SD. Group means ± SD were plotted with linear regression lines using graphics software (Grapher, Version 1.75, Golden Software, Golden, CO and Statview II, Abacus Concepts, Berkeley, CA). Biologic half-lives were calculated by the method of Rumack and Lovejoy (28) .
Results
Analysis of 1-NP-DNA Adducts Using 32P-Postlabeling Because multiple adducts were observed upon treatment of rats with 1-NP, including only one minor adduct spot (N-dG-AP) that was derived from nitroreduction (12), our current efforts were directed toward examining the nature and the origin of the other adducts. We prepared markers derived from ring-oxidized metabolites of 1-NP. The structures of 1-NP-4,5-oxide-DNA adducts were described previously (13) . The 32P-fingerprints of DNA that had been modified with 1-NP-4,5-oxide are shown in Figure  4 . By comparing chromatographic behaviors, we deduced that these oxide adducts may be responsible for the formation of some of the putative 1-NP-DNA adducts in vivo (12) . The 32P-maps of DNA modified with 1-NP-4,5-oxide in the presence of xanthine oxidase showed additional adduct spots, including those observed in the absence of xanthine oxidase (Figure 4 ). The maps of DNA modified with 1-NP-9,10-oxide in the presence and absence of xanthine oxidase were more complex ( Figure  4 ). Multiple adducts also were observed by the 32P-postlabeling assays of DNA that had been modified with 1-NP-x-OH (x = 3, 6, or 8, Figure 5 ) and trans-1-NP-4,5-DHD in the presence of xanthine oxidase ( Figure 6 ).
Analysis of Hemoglobin Adducts Fliowig the Or Adnistration of [3H] l-Nitropyrene to Rats
After dialysis, the hemoglobin solution was extracted with EtOAc. A putative 1-NP metabolite was covalently bound to the hemoglobin as evidenced by the absence of radioactivity in the EtOAc layer. [3H1-NP forms hemoglobin adducts at 0.08 ± 0.05% (mean ± SD, n = 3 rats) of the dose given orally in trioctanoin. The doseresponse data were obtained by measuring the radioactivity in the whole hemoglobin compartment (i.e., after dialysis but prior to acidic acetone treatment). Using linear regression analysis, the dose-response curve is linear over five orders of magnitude 2 (p<0.01, r = 0.963; Figure 2 ). Following the disappearance of radioactivity after administering a single dose of [3HI 1-NP, it appears that these adducts are cleared (by first-order kinetics with a halflife of about 14 days) faster than unmodified rat erythrocytes (28, 29) ; compare Figure  3A . Thus, these adducts would be expected to accumulate as a result of chronic exposure; this result was observed ( Figure 3B ). After cessation of dosing (after 35 Figure 3B . The rate of disappearance of the adducts in Figure 3B seems to be faster than that observed in Figure 3A . This is likely a result of differences between acute and chronic treatment among other factors (30) .
The hemoglobin was treated with 1% HC1 in acetone, to precipitate the globin; this released 80% of the initial radioactivity into the fraction containing the heme; the globin had no measurable radioactivity. Ethanol precipitation (31) of the globin, followed by successive washings with ethanol, ethanol-ether, and finally with ether, indicated that the radioactivity still remained bound tightly to the heme fraction, while globin had no measurable radioactivity. As shown in Figure 7A , using a C18 column and a H20/MeOH gradient, radioactive material eluted slightly after the unmodified heme; the arrow indicates the elution of the latter. This radioactive material did not coelute with any of the known 1-NP metabolites. We were not able to separate In vitro studies were performed to gain insight into the nature of the binding and to provide ample material for spectral analysis. We incubated [3H] 1-NOP and 3 [H] -NP-4,5-oxide with rat hemoglobin. 140 Both compounds bound to globin, the former more so (37% of the initial radioactivity) than the latter (25%). In addition, radioactivity from both compounds was also found to be associated with the heme fraction (-20%). The in vitro results do not exclude the possible contribution of these _ _.1 two metabolites to adduct formation in o so 70~vivo. However, we did not investigate further whether the radioactivity that was (42) . We attempted to elucidate the structure of 1-NP-hemoglobin adducts. Knowledge gained during the past decade on the metabolism of 1-NP led us to reason initially that nitroreduction could be responsible for hemoglobin binding via formation of 1-NOP. The latter compound would be expected to react with cysteine residues on hemoglobin. The adduct containing the sulfinamide bond would be labile under the acidic conditions used in this study for the hydrolysis of 1-NP-hemoglobin adducts. The acid hydrolysis of hemoglobin adducts revealed that none of the radioactivity remained bound to the globin and more than 80% of the initial radioactivity was recovered in the heme fraction. Concentrated acid and base treatments of the heme fraction did not release any detectable derivative of 1-NP, suggesting that the radioactivity was strongly bound to the heme moiety. Other compounds (for example phenylhydrazine, 3-alkylsydnones, diethylnitrosamine, aminobenzotriazole, and norethindrone) have also been shown to form adducts with the heme moiety of hemoglobin as well as with heme-containing enzymes (23) (24) (25) (26) (43) (44) (45) 
